Protara Therapeutics stockholders approve all five proposals at 2024 Annual Meeting

Protara Therapeutics, Inc.

Class I directors elected: Jane Huang (9.66M for), Richard Levy (9.64M for), Michael Solomon (9.56M for); broker non-votes 3.81M.
Ratification of Ernst & Young as auditor: 13.40M for, 189,574 against, 1,424 abstentions.
Advisory vote on exec compensation approved: 7.00M for, 196,457 against, 2.59M abstentions plus broker non-votes.
2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan both approved: 9.60M and 9.65M for, respectively.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.